# US 2026/0076897 A1 · Dry powder formulations of epinephrine and associated methods

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0076897 A1
- Document ID: US20260076897A1
- Status: Published application
- Kind: A1
- Application number: 19/402,382
- Filed: 2025-11-26
- Published: 2026-03-19
- Earliest claimed: 2021-06-10
- Assignees: Belhaven BioPharma Inc.
- Applicants: Belhaven BioPharma Inc.
- Inventors: Scott Lyman; Barry Bleske; Ted William Lanpher
- Web page: https://patentgrep.com/patent/US20260076897A1

## CPC

- A61K 9/0043: {Nose}
- A61K 31/137: Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone}
- A61K 31/417: Imidazole-alkylamines, e.g. histamine, phentolamine
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Provided herein are dry powder formulations comprising epinephrine alone or in combination with at least one enabling agent suitable for nasal application. Also provided are unit dose forms and devices comprising such formulations and methods of using such formulations for the treatment of various conditions including anaphylaxis, anaphylactoid reaction, respiratory conditions, hemodynamic collapse, and for administration during cardiopulmonary arrest and other life-threatening conditions.

## Claims

### Claim 1

A method for intranasal administration of a dry powder pharmaceutical composition comprising:
providing an intranasal device to a patient suffering from anaphylaxis, wherein the intranasal device includes a delivery head and a reservoir containing a dose of the dry powder pharmaceutical composition, wherein the dry powder pharmaceutical composition comprises:
a first active ingredient, wherein the first active ingredient comprises epinephrine or a pharmaceutically acceptable salt thereof;
a second active ingredient; and
a carrier;
actuating the intranasal device to deliver the dose of the dry powder pharmaceutical composition into a nasal cavity of the patient.

### Claim 2 (depends on 1)

The method of claim 1, wherein the carrier includes mannitol, a cyclodextrin, citric acid, lactose monohydrate, and/or sodium carboxymethylcellulose.

### Claim 3 (depends on 1)

The method of claim 1, wherein the second active ingredient is a vasodilator, a catechol-o-methyl transferase (COMT) inhibitor, an enabling agent, an antihistamine, a steroid, or sodium chloride.

### Claim 4 (depends on 1)

The method of claim 1, wherein the quantity of the dry powder pharmaceutical composition is between about 10 mg and about 40 mg.

### Claim 5 (depends on 1)

The method of claim 1, wherein the dry powder pharmaceutical composition does not include a preservative.

### Claim 6 (depends on 1)

The method of claim 1, wherein the first active ingredient comprises about 0.01 mg to about 10 mg of the epinephrine or the pharmaceutically acceptable salt thereof.

### Claim 7 (depends on 1)

The method of claim 1, wherein the dry powder pharmaceutical composition further comprises one or more agents selected from a group consisting of a mucosal permeation or penetration enhancer, a mucoadhesive, a mucosal transit slowing agent, a mucosal transport enhancer, or any combination thereof.

### Claim 8

A method for intranasal administration of a dry powder pharmaceutical composition comprising:
providing an intranasal device to a patient suffering from anaphylaxis, wherein the intranasal device includes a delivery head and a reservoir containing a dose of the dry powder pharmaceutical composition, wherein the dry powder pharmaceutical composition comprises:
at least one active ingredient, wherein the at least one active ingredient comprises about 0.01 mg to about 10 mg of epinephrine or a pharmaceutically acceptable salt thereof; and
a carrier;
actuating the intranasal device to deliver the dose of the dry powder pharmaceutical composition into a nasal cavity of the patient.

### Claim 9 (depends on 8)

The method of claim 8, wherein the dry powder pharmaceutical composition further comprises at least one second active ingredient.

### Claim 10 (depends on 9)

The method of claim 9, wherein the at least one second active ingredient is a vasodilator, a catechol-o-methyl transferase (COMT) inhibitor, an enabling agent, an antihistamine, a steroid, or sodium chloride.

### Claim 11 (depends on 8)

The method of claim 8, wherein the carrier includes mannitol, a cyclodextrin, citric acid, lactose monohydrate, and/or sodium carboxymethylcellulose.

### Claim 12 (depends on 8)

The method of claim 8, wherein the quantity of the dry powder pharmaceutical composition is between about 10 mg and about 40 mg.

### Claim 13 (depends on 8)

The method of claim 8, wherein the dry powder pharmaceutical composition does not include a preservative.

### Claim 14 (depends on 8)

The method of claim 8, wherein the dry powder pharmaceutical composition further comprises one or more agents selected from a group consisting of a mucosal permeation or penetration enhancer, a mucoadhesive, a mucosal transit slowing agent, a mucosal transport enhancer, or any combination thereof.

### Claim 15

A method for intranasal administration of a dry powder pharmaceutical composition comprising:
intranasally administering a single dose of a dry powder pharmaceutical composition, wherein the dry powder pharmaceutical composition comprises:
a first active ingredient, wherein the first active ingredient comprises about 0.01 mg to about 10 mg of epinephrine or a pharmaceutically acceptable salt thereof;
a second active ingredient; and
a carrier.

### Claim 16 (depends on 15)

The method of claim 15, wherein the carrier includes mannitol, a cyclodextrin, citric acid, lactose monohydrate, and/or sodium carboxymethylcellulose.

### Claim 17 (depends on 15)

The method of claim 15, wherein the second active ingredient is a vasodilator, a catechol-o-methyl transferase (COMT) inhibitor, an enabling agent, an antihistamine, a steroid, or sodium chloride.

### Claim 18 (depends on 15)

The method of claim 15, wherein the quantity of the dry powder pharmaceutical composition is between about 10 mg and about 40 mg.

### Claim 19 (depends on 15)

The method of claim 15, wherein the dry powder pharmaceutical composition does not include a preservative.

### Claim 20 (depends on 15)

The method of claim 15, wherein the dry powder pharmaceutical composition further comprises one or more agents selected from a group consisting of a mucosal permeation or penetration enhancer, a mucoadhesive, a mucosal transit slowing agent, a mucosal transport enhancer, or any combination thereof.
